A Phase 1, Multicenter, Open-label, Single Sequence Crossover Study to Evaluate Drug-drug Interaction Potential of OATP1B/CYP3A Inhibitor on the Pharmacokinetics of DS-8201a in Subjects With HER2-expressing Advanced Solid Malignant Tumors
Latest Information Update: 19 Feb 2024
At a glance
- Drugs Trastuzumab-deruxtecan (Primary) ; Itraconazole; Ritonavir
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer; Salivary gland cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Daiichi Sankyo Company
- 07 Dec 2023 Status changed from active, no longer recruiting to completed.
- 07 Sep 2023 Planned End Date changed from 30 Sep 2023 to 31 Mar 2024.
- 22 Mar 2023 Planned End Date changed from 31 Mar 2023 to 30 Sep 2023.